Most immuno-oncology drugs work by altering the tumor microenvironment to recruit and activate immune cells. However, resolving these complex tissue landscapes — identifying which cells are present, in what quantities, and in which functional states — at the depth, quality, and scale required for clinical trials has been a persistent challenge.
In this webinar, experts discuss how recent advances in multiplex immunofluorescence (mIF) are expanding the ability to profile complex cellular ecosystems, enabling more quantitative and spatially resolved insights in clinical research.
Topics to be covered:
- How new mIF approaches address key challenges in reagent validation, panel flexibility, and scalability for large clinical studies
- How integrating immune response and target biomarkers enables a more complete view of the tumor microenvironment
- How to apply high-plex mIF to support biomarker validation in clinical trials
